EX-99.1 2 d193159dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)

2 September 2016

Appendix 3B & Cleansing Notice

SYDNEY, AUSTRALIA – Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) Prima advises that in relation to the issuance of ordinary shares as further detailed in the attached Appendix 3B, the Company gives notice under section 708A(5)(e) of the Corporations Act 2001(Cth) (the “Corporations Act”) that:

 

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

 

2. as at the date of this notice the Company has complied with:

 

  (a) the provisions of Chapter 2M Corporations Act as they apply to the Company; and

 

  (b) section 674 Corporations Act; and

 

3. As at the date of this notice there is no “excluded information” (as defined in subsection 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

Yours faithfully

 

LOGO

Tom Bloomfield

Company Secretary

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889


Appendix 3B

New issue announcement

 

 

 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

 

Name of entity

Prima BioMed Ltd

 

ABN

90 009 237 889

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

1    +Class of +securities issued or to be issued       a)    Ordinary Shares
         b)    Ordinary Shares
           
2   

Number of +securities issued or to be issued (if known) or

maximum number which may be issued

      a)    7,333,333 ordinary shares on exercise of performance rights.
         b)    3 ordinary shares on exercise of an equivalent number of listed options (Options Exercise).
           

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 2  


Appendix 3B

New issue announcement

 

 

 

3   

Principal terms of the

+securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if

+convertible securities, the conversion price and dates for conversion)

     

a)

b)

  

Pari passu with existing Ordinary Shares (PRR)

Pari passu with existing Ordinary Shares (PRR)

               
4   

Do the +securities rank equally in all respects from the +issue date with an existing +class of

quoted +securities?

 

If the additional +securities do not rank equally, please state:

•       the date from which they do

•       the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

•       the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

      a)    Yes (PRR)
         b)    Yes (PRR)
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
               
           
5    Issue price or consideration       a)    nil
         b)    $0.20 per Share (with respect to the Shares issued following the Options Exercise).
               

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 3  


Appendix 3B

New issue announcement

 

 

 

6   

Purpose of the issue

(If issued as consideration for
the acquisition of assets, clearly
identify those assets)

        a)    Exercise of performance rights issued under the Executive Incentive Plan following
vesting on 5 August 2016.
         b)    Shares issued on Options Exercise.
             
             
               
           
 
6a   

Is the entity an +eligible entity

that has obtained security

holder approval under rule 7.1A?

 

If Yes, complete sections 6b – 6h

in relation to the +securities the

subject of this Appendix 3B, and

comply with section 6i

      Yes, although these securities are not being issued under Listing Rule 7.1A   
              
 
6b   

The date the security holder

resolution under rule 7.1A was

passed

      25 November 2015   
              
 
6c   

Number of +securities issued

without security holder approval

under rule 7.1

      n/a   
              
 
6d   

Number of +securities issued

with security holder approval under rule 7.1A

      n/a   
              
 
6e   

Number of +securities issued

with security holder approval under rule 7.3, or another

specific security holder approval (specify date of meeting)

      n/a   
              
6f   

Number of +securities issued

under an exception in rule 7.2

      a)    7,333,333 ordinary shares under exception 9(b)   
         b)    3 ordinary shares under exception 4   

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 4  


Appendix 3B

New issue announcement

 

 

 

6g    If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.       n/a   
                    
6h   

If +securities were issued under

rule 7.1A for non-cash

consideration, state date on

which valuation of consideration was released to ASX Market Announcements

      n/a   
                    
6i   

Calculate the entity’s remaining

issue capacity under rule 7.1 and

rule 7.1A – complete Annexure 1

and release to ASX Market

Announcements

      Refer Annexure 1   
                    
7   

+Issue dates

 

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

 

Cross reference: item 33 of Appendix 3B.

      2 September 2016   
                    
        

 

Number

 

  

 

+Class

 

  
8     

Number and +class of all

+securities quoted on ASX (including the +securities in

section 2 if applicable)

     

 

2,068,964,280

 

  

 

Ordinary shares

(ASX: PRR)

 

  
        

 

77,378,693

  

 

Options exercisable at $0.20 on or before 19 June 2017 (PRRO)

 

  
                    
        

 

Number                

 

  

 

+Class - Options

 

  
9    Number and +class of all      

 

Amount            

 

  

 

Exercise Price        

 

  

 

Expiration Date                

 

  
        

 

1,515,752  

 

  

 

$0.0774  

  

 

30 June 2018  

  
        

 

165,116  

 

  

 

$0.0774  

  

 

30 June 2018  

  
        

 

 

147,628,500  

 

  

 

$0.05019  

  

 

12 December 2018  

  
        

 

371,445,231  

 

  

 

$0.0237  

  

 

4 August 2020  

  
        

 

793,103  

 

  

 

$0.057  

  

 

30 October 2020  

  
        

 

1,026,272  

 

  

 

$0.040  

  

 

7 March 2021  

  
        

 

8,475,995  

 

  

 

$0.025  

  

 

4 August 2025  

  

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 5  


Appendix 3B

New issue announcement

 

 

 

        

 

Number

 

  

 

+Class - Performance Rights

 

  
        

 

Amount                

 

  

 

Type                

 

  

 

Expiration Date

 

  
        

 

1,538,462  

 

  

 

STI

 

  

 

1 December 2016  

 

  
        

 

1,486,326  

 

  

 

STI

 

  

 

5 August 2017  

 

  
        

 

30,918,333  

 

  

 

LTI

 

  

 

30 October 2018  

 

  
        

 

20,666,667  

  

 

PRs

  

 

The PRs will expire between   30 days to 12 months  

after the vesting date  

of 5 August 2017  

 

  
        

 

3,431,373  

  

 

NED PRs

  

 

Each tranche of NED PRs will  

expire 30 days from  

each tranche vesting  

date indicated in the  

appendix 3B released  

on 26 November 2014.  

 

  
        

 

13,750,828  

  

 

Convertible Notes each with a face value of  

AU$1, expiring on 4 August 2025  

 

  
                    
10    Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)       Unchanged   
                    
Part 2 - Pro rata issue   
                    
11    Is security holder approval required?       n/a   
                    
12    Is the issue renounceable or non-renounceable?       n/a   
                    
13    Ratio in which the +securities will be offered       n/a   
                    
14    +Class of +securities to which the offer relates       n/a   
                    
15    +Record date to determine entitlements       n/a   
                    
16    Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?       n/a   

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 6  


Appendix 3B

New issue announcement

 

 

 

17    Policy for deciding entitlements in relation to fractions       n/a   
                    
18   

Names of countries in which the entity has security holders who will not be sent new offer documents

 

Note: Security holders must be told how their entitlements are to be dealt with.

 

Cross reference: rule 7.7.

      n/a   
                    
19    Closing date for receipt of acceptances or renunciations       n/a   
                    
20    Names of any underwriters      

n/a

 

  
                    
21    Amount of any underwriting fee or commission       n/a   
                    
22    Names of any brokers to the issue      

n/a

 

  
                    
23    Fee or commission payable to the broker to the issue       n/a   
                    
24    Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders       n/a   
                    
25    If the issue is contingent on security holders’ approval, the date of the meeting       n/a   
                    
26    Date entitlement and acceptance form and offer documents will be sent to persons entitled       n/a   
                    
27    If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders       n/a   
                    
28    Date rights trading will begin (if applicable)       n/a   
                    

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 7  


Appendix 3B

New issue announcement

 

 

 

 

29    Date rights trading will end (if applicable)       n/a   
                    
30    How do security holders sell their entitlements in full through a broker?       n/a   
                    
31    How do security holders sell part of their entitlements through a broker and accept for the balance?       n/a   
                    
32    How do security holders dispose of their entitlements (except by sale through a broker)?       n/a   
                    
33    +Issue date      

n/a

 

  
                    

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

 

34   

Type of +securities

(tick one)

     
(a)    x    +Securities described in Part 1
     
(b)    ¨   

All other +securities

 

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

     
Entities that have ticked box 34(a)
     
Additional securities forming a new class of securities
     
Tick to indicate you are providing the information or documents
     
35    ¨    If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
     

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 8  


Appendix 3B

New issue announcement

 

 

 

 

36    ¨   

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

     
37    ¨    A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

 

38    Number of +securities for which +quotation is sought       n/a   
                    
39    +Class of +securities for which quotation is sought       n/a   
                    
40   

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

      n/a   
     •    the date from which they do           
     •    the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment           
     •    the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment           
                    
41   

Reason for request for quotation now

 

Example: In the case of restricted securities, end of restriction period

 

(if issued upon conversion of another +security, clearly identify that other +security)

      n/a   
                    
         Number                                             +Class   
42    Number and +class of all +securities quoted on ASX (including the +securities in clause 38)       n/a        

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 9  


Appendix 3B

New issue announcement

 

 

 

Quotation agreement

 

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

 

2 We warrant the following to ASX.

 

    The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 

    There is no reason why those +securities should not be granted +quotation.

 

    An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

    Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 

    If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

 

Sign here:     LOGO                        Date: 2 September 2016   
    Company Secretary         
Print name:     Tom Bloomfield         

 

 

+ See chapter 19 for defined terms.

 

04/03/2013   Appendix 3B Page 10  


Appendix 3B – Annexure 1

Calculation of placement capacity under

rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

 

Rule 7.1 – Issues exceeding 15% of capital

 

 

  

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

 

 

  

Insert number of fully paid +ordinary

securities on issue 12 months before the +issue date or date of agreement to issue

 

 

  

 

1,974,298,018

  

Add the following:

 

 

       
•    

Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

 

   23,644,081   
 

Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

 

       
  Number of partly paid +ordinary securities that became fully paid in that 12 month period        

 

Note:

       
 

Include only ordinary securities here – other

classes of equity securities cannot be added

 

       
 

Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

 

       
 

It may be useful to set out issues of securities on different dates as separate line items

 

       

Subtract the number of fully paid +ordinary securities cancelled during that 12 month

period

 

 

  

 

Nil

  

 

“A”

 

  

 

1,997,942,099

  


 

Step 2: Calculate 15% of “A”

 

  

 

“B”

  

0.15

 

[Note: this value cannot be changed]

 

  

 

Multiply “A” by 0.15

 

  

 

299,691,315

 

  

 

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

 

  

 

Insert number of +equity securities issued or

agreed to be issued in that 12 month period not

counting those issued:

 

  

 

41,819,375

  
•    

Under an exception in rule 7.2

 

       
•    

Under rule 7.1A

 

       
•    

With security holder approval under rule 7.1

or rule 7.4

 

       

Note:

 

       
•    

This applies to equity securities, unless

specifically excluded – not just ordinary

securities

 

       
•    

Include here (if applicable) the securities the

subject of the Appendix 3B to which this

form is annexed

 

       
•    

It may be useful to set out issues of

securities on different dates as separate line

items

 

       

 

“C”

 

  

 

41,819,375

 

  

 

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

 

  

 

“A” x 0.15

 

Note: number must be same as shown in Step 2

 

  

 

299,691,315

  

 

Subtract “C”

 

Note: number must be same as shown in Step 3

 

  

 

41,819,375

  

 

Total [“A” x 0.15] – “C”

  

 

257,871,940

 

[Note: this is the remaining placement capacity under rule 7.1]

 

  

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889


 

Part 2

 

  

 

Rule 7.1A – Additional placement capacity for eligible entities

 

  

 

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

 

  

 

“A”

 

Note: number must be same as shown in

Step 1 of Part 1

 

  

 

1,997,942,099

  

 

Step 2: Calculate 10% of “A”

 

  

 

“D”

  

 

0.10

 

Note: this value cannot be changed

 

  

 

Multiply “A” by 0.10

 

  

 

199,794,210

 

  

 

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

 

  

 

Insert number of +equity securities issued or

agreed to be issued in that 12 month period

under rule 7.1A

 

  

 

31,022,181

  

Notes:

 

       
•    

This applies to equity securities – not just

ordinary securities

 

       
•    

Include here – if applicable – the securities the  

subject of the Appendix 3B to which this form

is annexed

 

       
•    

Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

 

       
•    

It may be useful to set out issues of securities on different dates as separate line items

 

       

 

“E”

 

  

 

31,022,181

 

  

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889


 

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

 

  

 

“A” x 0.10

 

Note: number must be same as shown in Step 2  

 

  

 

199,794,210

  

 

Subtract “E”

 

Note: number must be same as shown in Step 3  

 

  

 

31,022,181

  

 

Total [“A” x 0.10] – “E”

  

 

168,772,029

 

Note: this is the remaining placement capacity under rule 7.1A

 

  

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889